Breaking News, Financial News

1Q Financial Report: Bristol-Myers Squibb

1Q Revenues: $4.7 billion (+3%)

1Q Earnings: $714 million (+33%)

Comments: Plavix, Avapro/Avalide, Abilify, Reyataz and Erbitux all delivered double-digit sales increases. The company launched RA biologic Orencia and received additional approval for Erbitux during 1Q2006. U.S. pharmaceutical revenues rose 17% to $2.1 billion, while international pharma sales dropped 10%, including a 5% drop due to exchange rates, to $1.6 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters